News

Protein may be marker of disease activity, kidney damage in AAV

A protein known as NGAL — fully, neutrophil gelatinase-associated lipocalin — appears to be a marker of disease activity and kidney damage severity in people with ANCA-associated vasculitis (AAV) who have kidney inflammation, according to new research by scientists in China. The team found that “in active AAV, [blood]…

Researchers identify markers of kidney disease common in AAV

Most people who test positive for ANCAs — the self-reactive antibodies that drive most ANCA-associated vasculitis (AAV) cases — have pauci-immune glomerulonephritis (GN), a type of inflammation of the kidneys’ filtering units, a study found. A high number of blood-clotting-inducing platelets, high blood levels of the inflammatory marker…

Tavneos combo works as well as steroids for AAV remission

Similar rates of remission and sustained remission were found for people with ANCA-associated vasculitis (AAV) given induction treatment with cyclophosphamide and Tavneos (avacopan) in a clinical trial compared with those receiving cyclophosphamide plus the glucocorticoid prednisone. Still, the Tavneos-based treatment regimen appeared to be associated with a lower…

AAV linked to higher risk of nonmelanoma skin cancer

People with ANCA-associated vasculitis (AAV) are at a higher risk of developing nonmelanoma skin cancer (NMSC), the most common form of skin cancer, but not other types of cancer, according to a long-term follow-up study in Europe. The use of the immunosuppressive therapy azathioprine, longer azathioprine treatment, and being…

Worse prognosis for AAV patients with pulmonary renal syndrome

Having pulmonary renal syndrome (PRS), a potentially life-threatening condition marked by lung and kidney problems, is associated with a higher risk of severe complications in people with ANCA-associated vasculitis (AAV), a new study reports. After accounting for starting differences in kidney function, AAV patients with PRS had a six…

Rituximab treatment can boost survival, slash AAV relapse rate

In severe ANCA-associated vasculitis (AAV), rituximab may be superior to cyclophosphamide at helping people survive beyond 10 years and achieve remission, while reducing the need for standard corticosteroids. These are the findings of a Japanese real-world study that also found rituximab was not associated with any infection-related deaths,…